712 related articles for article (PubMed ID: 33171486)
1. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
2. Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.
Falini B; Dillon R
Blood Cancer Discov; 2024 Jan; 5(1):8-20. PubMed ID: 37917833
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.
Falini B; Sciabolacci S; Falini L; Brunetti L; Martelli MP
Leukemia; 2021 Nov; 35(11):3113-3126. PubMed ID: 33879827
[TBL] [Abstract][Full Text] [Related]
4. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
5. NPM1-mutated acute myeloid leukemia: from bench to bedside.
Falini B; Brunetti L; Sportoletti P; Martelli MP
Blood; 2020 Oct; 136(15):1707-1721. PubMed ID: 32609823
[TBL] [Abstract][Full Text] [Related]
6. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
7. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
8. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
10.
Höllein A; Meggendorfer M; Dicker F; Jeromin S; Nadarajah N; Kern W; Haferlach C; Haferlach T
Blood Adv; 2018 Nov; 2(22):3118-3125. PubMed ID: 30455361
[TBL] [Abstract][Full Text] [Related]
11. Bone Marrow Clonogenic Myeloid Progenitors from
Guardia RD; González-Silva L; López-Millán B; Rodríguez-Sevilla JJ; Baroni ML; Bueno C; Anguita E; Vives S; Palomo L; Lapillonne H; Varela I; Menendez P
Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31936647
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Andrews C; Maze D; Murphy T; Sibai H
Br J Haematol; 2020 Aug; 190(3):467-470. PubMed ID: 32567045
[No Abstract] [Full Text] [Related]
13. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
[TBL] [Abstract][Full Text] [Related]
14. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
[TBL] [Abstract][Full Text] [Related]
15. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
16. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
Schnittger S; Kern W; Tschulik C; Weiss T; Dicker F; Falini B; Haferlach C; Haferlach T
Blood; 2009 Sep; 114(11):2220-31. PubMed ID: 19587375
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
19. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
20. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]